← Product Code [LJT](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LJT) · K962230 # CELSITE PORT WITH PRECONNECTED CATHETER (K962230) _B.Braun Medical, Inc. · LJT · Dec 16, 1996 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LJT/K962230 ## Device Facts - **Applicant:** B.Braun Medical, Inc. - **Product Code:** [LJT](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LJT.md) - **Decision Date:** Dec 16, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.5965 - **Device Class:** Class 2 - **Review Panel:** General Hospital - **Attributes:** Therapeutic ## Indications for Use The Celsite™ Port with Preconnected Catheter is an implanted port with a catheter system attached which allows safe, repeated access to the patient's bloodstream. The port chamber and catheter design can be used for the administration of medications and fluids. ## Device Story Implanted port and preconnected catheter system; provides repeated intravascular access for medication/fluid administration. Device implanted by physician; used in clinical settings. Preconnected catheter design offers alternative to intra-operative catheter attachment. System facilitates long-term venous access; reduces need for repeated venipuncture; improves patient comfort/safety during therapy. ## Clinical Evidence No clinical data provided. Safety and effectiveness supported by established history of implanted ports, literature review, and MDR analysis demonstrating low risk profile. ## Technological Characteristics Implanted port and catheter system. Materials tested per Tripartite Guidance for Plastics. Design allows for preconnected catheter configuration. No electronic, software, or energy-based components. ## Regulatory Identification A subcutaneous, implanted, intravascular infusion port and catheter is a device that consists of a subcutaneous, implanted reservoir that connects to a long-term intravascular catheter. The device allows for repeated access to the vascular system for the infusion of fluids and medications and the sampling of blood. The device consists of a portal body with a resealable septum and outlet made of metal, plastic, or combination of these materials and a long-term intravascular catheter is either preattached to the port or attached to the port at the time of device placement. The device is available in various profiles and sizes and can be of a single or multiple lumen design. ## Special Controls *Classification.* Class II (special controls) Guidance Document: “Guidance on 510(k) Submissions for Implanted Infusion Ports,” FDA October 1990. ## Predicate Devices - CELSITE™ Venous Access System ([K952548](/device/K952548.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K962230 II 510(k) Summary DEC 16 1996 May 30, 1996 B. Braun Medical, Inc 824 Twelfth Avenue Bethlehem, PA 18018 (610) 691-5400 CONTACT: Mark S. Alsberge, Regulatory Affairs Manager PRODUCT NAME: Celsite™ Port wit Preconnected Catheter TRADE NAME: Celsite™ Implanted Ports & Catheters CLASSIFICATION NAME: General Hospital Devices Class III, 80 LJT Implanted Port & Catheter, Intravascular, Infusion SUBSTANTIAL EQUIVALENCE¹ TO: | 510(k) number | Name | Applicant | | --- | --- | --- | | K952548 | CELSITE™ Venous Access System | B. Braun Medical | DEVICE DESCRIPTION: The Celsite™ Port with Preconnected Catheter is an implanted port with a catheter system attached which allows safe, repeated access to the patient's bloodstream. The port chamber and catheter design can be used for the administration of medications and fluids. ¹ The term "substantially equivalent" as use herein is intended to be a determination of substantial equivalence from a FDA -regulatory point of view under the Federal Food, Drug, and Cosmetic Act and relates to the fact that the product can be marketed without premarket approval or reclassification. These products may be considered distinct from a patent point of view. The term "substantially equivalent" is not applicable to and does not diminish any patent claims related to this product or the technology used to manufacture the product. MATERIAL: The Celsite™ Port with Preconnected Catheter is composed of materials that have been tested in accordance with Tripartite Guidance for Plastics and determined to be suitable for the intended use of this product. 4 {1} SUBSTANTIAL EQUIVALENCE: B.Braun has marketed the CELSITE™ Venous Access System since it's clearance by the FDA in 1995 (K952548). The Celsite™ Port with preconnected catheter has the same intended use and functions in the same manner as the previous celsite™ ports. Connecting the catheter during insertion or having the catheter preconnected is a matter of physician preference and has no impact on the safety or effectiveness of the device. The implant bodies and catheters of the system are made of materials identical to those available in the original submission. Currently marketed ports incorporate features and are available from a number of manufacturers. A review of the current literature and MDRs indicate that there are no additional risks or concerns associated with this modification to the port designs. SAFETY AND EFFECTIVENESS: The manufacturing site, B.Braun Celsa in France, is scheduled to be inspected by the FDA in early June of this year and has passed its previous inspection in 1995. Implanted ports for intravascular access have become quite common with tens of thousands implanted yearly. Considering the number of ports implanted yearly verses the number of MDRs, implanted ports have demonstrated themselves on the whole to be safe and effective devices. --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LJT/K962230](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LJT/K962230) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com